Win4SpinOff supports VENOM2 in exploring the potential of venom-derived peptides in oncology

VENOM2 (Venom-based Exploration for Novel Oncology Molecules) aims to explore the unique potential of peptides derived from animal venoms and their applications in precision oncology. The project has recently received funding from Win4SpinOff, a programme run by SPW Research that supports the maturation of research results with a view to creating spin-off companies in Wallonia.

VENOM2 brings together complementary scientific strengths through a collaboration between UNamur and ULiège. Prof. Jean-Pierre Gillet (UNamur, NARILIS, Laboratory of Molecular Cancer Biology) has recognized expertise in cancer resistance mechanisms, while Prof. Loïc Quinton (ULiège, Molecular Systems Laboratory) brings extensive expertise in mass spectrometry, proteomics and the analysis of complex biological mixtures, such as animal venoms.

The work is led by Lou Freuville, who is pursuing a joint doctoral thesis between UNamur and ULiège. Her research focuses on identifying bioactive molecules that can selectively target cancer cells, including those that are resistant to current treatments. What makes VENOM2 unique is its dual objective of advancing both diagnosis and treatment. On the one hand, certain peptides could be used as targeting agents in molecular imaging, contributing to more accurate tumor detection and better patient stratification. On the other hand, other candidates could act as specific modulators of biological pathways involved in tumor progression, thereby paving the way for new therapeutic approaches. This dual focus reinforces both the project’s commercialization potential and its expected clinical impact.

Securing this Win4SpinOff funding represents a significant recognition of the scientific originality and commercialization potential of this research. It marks a key milestone in the development of new biomedical approaches inspired by biodiversity.